Active, not recruitingPHASE1, PHASE2NCT05121376

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Studying Hereditary angioedema

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
BioMarin Pharmaceutical
Principal Investigator
MD Medical Director
BioMarin Pharmaceutical
Intervention
Dose 1 of BMN 331(genetic)
Enrollment
44 enrolled
Eligibility
18 years · All sexes
Timeline
20222028

Study locations (16)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05121376 on ClinicalTrials.gov

Other trials for Hereditary angioedema

Additional recruiting or active studies for the same condition.

See all trials for Hereditary angioedema

← Back to all trials